GlaxoSmithKline Cash Per Share from 2010 to 2024

GSK Stock  USD 34.13  0.20  0.58%   
GlaxoSmithKline PLC Cash Per Share yearly trend continues to be quite stable with very little volatility. The value of Cash Per Share is projected to decrease to 0.69. From the period between 2010 and 2024, GlaxoSmithKline PLC, Cash Per Share regression line of its data series had standard deviation of  0.40 and standard deviation of  0.40. View All Fundamentals
 
Cash Per Share  
First Reported
2010-12-31
Previous Quarter
1.27887463
Current Value
0.69
Quarterly Volatility
0.40171858
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check GlaxoSmithKline PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GlaxoSmithKline PLC's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.4 B, Interest Expense of 502.2 M or Total Revenue of 19.9 B, as well as many indicators such as Price To Sales Ratio of 1.84, Dividend Yield of 0.0451 or PTB Ratio of 8.65. GlaxoSmithKline financial statements analysis is a perfect complement when working with GlaxoSmithKline PLC Valuation or Volatility modules.
  
Check out the analysis of GlaxoSmithKline PLC Correlation against competitors.

Latest GlaxoSmithKline PLC's Cash Per Share Growth Pattern

Below is the plot of the Cash Per Share of GlaxoSmithKline PLC ADR over the last few years. It is GlaxoSmithKline PLC's Cash Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in GlaxoSmithKline PLC's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.32 X10 Years Trend
Pretty Stable
   Cash Per Share   
       Timeline  

GlaxoSmithKline Cash Per Share Regression Statistics

Arithmetic Mean1.22
Geometric Mean1.13
Coefficient Of Variation32.92
Mean Deviation0.29
Median1.28
Standard Deviation0.40
Sample Variance0.16
Range1.7065
R-Value0.25
Mean Square Error0.16
R-Squared0.06
Significance0.36
Slope0.02
Total Sum of Squares2.26

GlaxoSmithKline Cash Per Share History

2024 0.69
2022 1.96
2021 1.35
2020 1.6
2019 1.21
2018 1.01
2017 1.0

About GlaxoSmithKline PLC Financial Statements

GlaxoSmithKline PLC investors utilize fundamental indicators, such as Cash Per Share, to predict how GlaxoSmithKline Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Cash Per Share 1.28  0.69 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:
Check out the analysis of GlaxoSmithKline PLC Correlation against competitors.
You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.28)
Dividend Share
0.61
Earnings Share
1.54
Revenue Per Share
15.38
Quarterly Revenue Growth
(0.02)
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.